Abstract
Ospemifene has been marketed in the US since 2013 to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. This study used real-world data to estimate the incidence rates of breast cancer in VVA patients without a history of breast cancer treated with ospemifene, and in similar patients without any VVA related treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
